Brokers Set Expectations for BioNTech FY2024 Earnings

BioNTech SE (NASDAQ:BNTX) – Stock analysts at HC Wainwright issued their FY2024 EPS estimates for BioNTech in a research report issued on Monday, March 10th. HC Wainwright analyst R. Burns expects that the company will earn ($5.24) per share for the year. HC Wainwright currently has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at ($3.42) EPS, Q2 2025 earnings at ($3.50) EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($6.43) EPS.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.90 EPS.

Several other equities research analysts have also recently issued reports on the stock. BMO Capital Markets lifted their target price on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday. Truist Financial assumed coverage on BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday. Wells Fargo & Company began coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. Finally, Morgan Stanley cut their target price on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $143.65.

BioNTech Stock Up 2.0 %

Shares of NASDAQ BNTX opened at $100.31 on Wednesday. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company’s 50-day simple moving average is $116.18 and its 200-day simple moving average is $113.04. The firm has a market cap of $24.05 billion, a price-to-earnings ratio of -47.77 and a beta of 0.30.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Planning Capital Management Corp raised its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. raised its holdings in shares of BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE purchased a new stake in shares of BioNTech during the 4th quarter worth $90,000. Finally, GAMMA Investing LLC grew its stake in shares of BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.